|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4439 | |
| A61K 31/517 | |||
| A61K 39/395 | |||
| A61K 45/06 | |||
| A61P 35/00 | |||
| C07K 16/32 | |||
| A61K 39/00 |
| (11) | Patento numeris | 2637661 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11782111.6 |
| Europos patento paraiškos padavimo data | 2011-11-07 | |
| (97) | Europos patento paraiškos paskelbimo data | 2013-09-18 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2017-12-20 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (86) | Numeris | PCT/EP2011/069522 |
| Data | 2011-11-07 |
| (87) | Numeris | WO 2012/062694 |
| Data | 2012-05-18 |
| (30) | Numeris | Data | Šalis |
| 411117 P | 2010-11-08 | US |
| (72) |
BRACHMANN, Saskia Maria, CH
FRITSCH, Christine, CH
MAIRA, Sauveur-Michel, CH
SCHNELL, Christian René, CH
GARCIA-ECHEVERRIA, Carlos, FR
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E |
| Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target E |